Advertisement

Endocrine

pp 1–7 | Cite as

Increased waist-to-hip ratio is associated with decreased urine glucose excretion in adults with no history of diabetes

  • Juan Chen
  • Shanhu Qiu
  • Haijian Guo
  • Wei Li
  • Zilin SunEmail author
Original Article
  • 78 Downloads

Abstract

Purpose

Promoting urine glucose excretion (UGE) is an attractive approach for the treatment of diabetes. Obesity is associated with increased risk for type 2 diabetes. This study was aimed to investigate the association of waist-to-hip ratio (WHR), a simple measure of abdominal obesity, with UGE determined in subjects without previous history of diabetes.

Methods

We studied the correlation of WHR with UGE in 7485 participants without previous history of diabetes. All participants were given a standard 75 g glucose solution. Clinical parameters and demographic characteristics were assessed. Multiple linear regression analysis and multivariate logistic regression analysis were performed to determine the association of WHR with UGE.

Results

Individuals with high WHR (H-WHR) exhibited significantly lower UGE compared to those with low WHR (L-WHR), in either normal glucose tolerance group or pre-diabetes group. In newly diagnosed diabetes group, individuals with H-WHR also showed lower UGE than those with L-WHR; however, no statistical significance was observed. After adjustment for potential confounding factors, including age, genders, and blood glucose level, WHR was negatively associated with UGE (β = −250.901, 95% CI: −471.891 to −29.911, p = 0.026). However, no significant association was observed between BMI and UGE. Furthermore, multivariable logistic regression model showed that individuals with H-WHR were more likely to have low UGE (OR = 0.83, 95% CI: 0.71–0.97, p = 0.018).

Conclusions

Individuals with H-WHR were at risk for decreased UGE. This study suggests that WHR, but not BMI, might be an important determinant of UGE.

Keywords

Urine glucose excretion Obesity Waist-to-hip ratio Renal glucose reabsorption 

Notes

Acknowledgements

We owe our sincere thanks to the local research teams and colleagues for assistance in participant recruitment. We are grateful to many residents of Jiangsu Province who participated in this study. We thank all the staff who were involved in this study for their important contributions.

Funding

This study was supported by grants from the Excellence Project of Southeast University, the National Key R&D Program of China (2016YFC1305700) and the National Key Scientific Instrument and Equipment Development Project of China (No. 51627808). The funders had no roles in study design, data collection, data analysis, interpretation or writing the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the ethical review committee of Jiangsu Provincial Center for Disease Control and Prevention (JSJK2016-B003-03).

Informed consent

Informed consent was obtained from all participants included in the study.

References

  1. 1.
    J.E. Gerich, Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet. Med. 27, 136–142 (2010)CrossRefGoogle Scholar
  2. 2.
    R.A. DeFronzo, J.A. Davidson, P.S. Del, The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14, 5–14 (2012)CrossRefGoogle Scholar
  3. 3.
    R.A. DeFronzo, M. Hompesch, S. Kasichayanula, X. Liu, Y. Hong, M. Pfister, L.A. Morrow, B.R. Leslie, D.W. Boulton, A. Ching, F.P. LaCreta, S.C. Griffen, Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169–3176 (2013)CrossRefGoogle Scholar
  4. 4.
    A. Osaki, S. Okada, T. Saito, E. Yamada, K. Ono, Y. Niijima, H. Hoshi, M. Yamada, Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy. J. Diabetes Investig. 7, 751–754 (2016)CrossRefGoogle Scholar
  5. 5.
    J.P. Wilding, The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metab. Clin. Exp. 63, 1228–1237 (2014)CrossRefGoogle Scholar
  6. 6.
    E. Ferrannini, Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 27–38 (2017)CrossRefGoogle Scholar
  7. 7.
    J. Chen, H. Guo, S. Yuan, C. Qu, T. Mao, S. Qiu, W. Li, X. Wang, M. Cai, H. Sun, B. Wang, X. Li, Z. Sun, Efficacy of urinary glucose for diabetes screening: a reconsideration. Acta Diabetol. (2018).  https://doi.org/10.1007/s00592-018-1212-1
  8. 8.
    J. Lu, R.F. Bu, Z.L. Sun, Q.S. Lu, H. Jin, Y. Wang, S.H. Wang, L. Li, Z.L. Xie, B.Q. Yang, Comparable efficacy of self-monitoring of quantitative urine glucose with self-monitoring of blood glucose on glycaemic control in non-insulin-treated type 2 diabetes. Diabetes Res. Clin. Pract. 93, 179–186 (2011)CrossRefGoogle Scholar
  9. 9.
    C.P. Kovesdy, S.L. Furth, C. Zoccali, Obesity and kidney disease: hidden consequences of the epidemic. Afr. J. Prim. Health Care Fam. Med. 9, e1–1e3 (2017)CrossRefGoogle Scholar
  10. 10.
    A. Misra, L. Khurana, Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int. J. Obes. (Lond.). 35, 167–187 (2011)CrossRefGoogle Scholar
  11. 11.
    A. Chandra, M. Biersmith, R. Tolouian, Obesity and kidney protection. J. Nephropathol. 3, 91–97 (2014)PubMedPubMedCentralGoogle Scholar
  12. 12.
    S.J. Pinto-Sietsma, G. Navis, W.M. Janssen, D. de Zeeuw, R.O. Gans, P.E. de Jong, A central body fat distribution is related to renal function impairment, even in lean subjects. Am. J. Kidney Dis. 41, 733–741 (2003)CrossRefGoogle Scholar
  13. 13.
    JI. Lakkis, MR. Weir, Obesity and kidney disease. Prog. Cardiovasc. Dis. 61, 157–167 (2018).CrossRefGoogle Scholar
  14. 14.
    X.D. Yue, J.Y. Wang, X.R. Zhang, J.H. Yang, C.Y. Shan, M.Y. Zheng, H.Z. Ren, Y. Zhang, S.H. Yang, Z.H. Guo, B. Chang, B.C. Chang, Characteristics and impact factors of renal threshold for glucose excretion in patients with type 2 diabetes mellitus. J. Korean Med. Sci. 32, 621–627 (2017)CrossRefGoogle Scholar
  15. 15.
    S. Yusuf, S. Hawken, S. Ounpuu, L. Bautista, M.G. Franzosi, P. Commerford, C.C. Lang, Z. Rumboldt, C.L. Onen, L. Lisheng, S. Tanomsup, P. Wangai, F. Razak, A.M. Sharma, S.S. Anand, Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366, 1640–1649 (2005)CrossRefGoogle Scholar
  16. 16.
    J.P. Reis, C.A. Macera, M.R. Araneta, S.P. Lindsay, S.J. Marshall, D.L. Wingard, Comparison of overall obesity and body fat distribution in predicting risk of mortality. Obesity (Silver Spring) 17, 1232–1239 (2009)Google Scholar
  17. 17.
    J. Chen, H.J. Guo, S.H. Qiu, W. Li, X.H. Wang, M. Cai, B. Wang, X.N. Li, Z.L. Sun, Identification of newly diagnosed diabetes and prediabetes using fasting plasma glucose and urinary glucose in a Chinese population: a multicenter cross-sectional study. Chin. Med. J. 131, 1652–1657 (2018)CrossRefGoogle Scholar
  18. 18.
    M.A. van Baak, The peripheral sympathetic nervous system in human obesity. Obes. Rev. 2, 3–14 (2001)CrossRefGoogle Scholar
  19. 19.
    R.H. Elliott, V.B. Matthews, C. Rudnicka, M.P. Schlaich, Is it time to think about the sodium glucose co-transporter 2 sympathetically? Nephrology (Carlton) 21, 286–294 (2016)CrossRefGoogle Scholar
  20. 20.
    W. Ji, M. Zhao, M. Wang, W. Yan, Y. Liu, S. Ren, J. Lu, B. Wang, L. Chen, Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One 12, e0179960 (2017)CrossRefGoogle Scholar
  21. 21.
    S. Fujioka, Y. Matsuzawa, K. Tokunaga, S. Tarui, Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metab. Clin. Exp. 36, 54–59 (1987)CrossRefGoogle Scholar
  22. 22.
    S.B. Solerte, M. Fioravanti, S. Severgnini, M. Rondanelli, S. Precerutti, G. Vignati, E. Ferrari, Hyperinsulinemia and glucagon serum concentrations influence renal hemodynamics and urinary protein loss in normotensive patients with central obesity. Int. J. Obes. Relat. Metab. Disord. 24(Suppl 2), S122–S123 (2000)CrossRefGoogle Scholar
  23. 23.
    N. Nakamura, T. Matsui, Y. Ishibashi, S. Yamagishi, Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetol. Metab. Syndr. 7, 48 (2015)CrossRefGoogle Scholar
  24. 24.
    J.E. Hall, E.D. Crook, D.W. Jones, M.R. Wofford, P.M. Dubbert, Mechanisms of obesity-associated cardiovascular and renal disease. Am. J. Med. Sci. 324, 127–137 (2002)CrossRefGoogle Scholar
  25. 25.
    K. Nagai, S. Yoshida, H. Konishi, Gender differences in the gene expression profiles of glucose transporter GLUT class I and SGLT in mouse tissues. Pharmazie 69, 856–859 (2014)PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of MedicineSoutheast UniversityNanjingChina
  2. 2.Department of Integrated ServicesJiangsu Provincial Center for Disease Control and PreventionNanjingChina

Personalised recommendations